Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

▤ Summary

Pharvaris shared new clinical data for deucrictibant at EAACI 2026, highlighting results across on-demand and prophylactic HAE treatment studies. The company reported rapid symptom relief, durable attack prevention, and favorable tolerability across its Phase 3 and long-term extension programs. It also presented integrated cardiovascular safety data showing no evidence of QT prolongation or clinically meaningful cardiac risk. In addition, Pharvaris described a clinically validated kinin biomarker assay that may help differentiate bradykinin-mediated angioedema from mast cell-mediated disease.

▦ Linked Companies